Dimensional Fund Advisors LP Deciphera Pharmaceuticals, Inc. Transaction History

Dimensional Fund Advisors LP

$403 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$13.58 - $17.36 $604,011 - $772,138	44,478 Added 2.85%	1,606,132 $25.3 Million
Q4 2023 Feb 07, 2024	BUY	$10.11 - $16.54 $934,265 - $1.53 Million	92,410 Added 6.29%	1,561,654 $25.2 Million
Q3 2023 Nov 09, 2023	BUY	$12.46 - $15.48 $756,695 - $940,100	60,730 Added 4.31%	1,469,244 $18.7 Million
Q2 2023 Aug 09, 2023	BUY	$13.28 - $15.96 $487,615 - $586,019	36,718 Added 2.68%	1,408,514 $19.8 Million
Q1 2023 May 12, 2023	BUY	$14.26 - $22.1 $4.21 Million - $6.52 Million	294,987 Added 27.39%	1,371,796 $21.2 Million
Q4 2022 Feb 09, 2023	BUY	$14.85 - $19.04 $434,748 - $557,415	29,276 Added 2.79%	1,076,809 $17.6 Million
Q3 2022 Nov 10, 2022	BUY	$12.38 - $20.23 $3.09 Million - $5.05 Million	249,777 Added 31.31%	1,047,533 $19.4 Million
Q2 2022 Aug 12, 2022	BUY	$9.11 - $13.98 $4.58 Million - $7.03 Million	502,737 Added 170.41%	797,756 $10.5 Million
Q1 2022 May 13, 2022	SELL	$6.87 - $11.11 $17,353 - $28,063	-2,526 Reduced 0.85%	295,019 $2.74 Million
Q4 2021 Feb 09, 2022	BUY	$7.7 - $37.13 $609,778 - $2.94 Million	79,192 Added 36.27%	297,545 $2.91 Million
Q3 2021 Nov 12, 2021	BUY	$26.46 - $37.15 $3.22 Million - $4.52 Million	121,800 Added 126.15%	218,353 $7.42 Million
Q2 2021 Aug 12, 2021	SELL	$32.73 - $47.95 $79,239 - $116,086	-2,421 Reduced 2.45%	96,553 $3.54 Million
Q1 2021 May 14, 2021	BUY	$40.39 - $56.73 $1.63 Million - $2.29 Million	40,447 Added 69.11%	98,974 $4.45 Million
Q4 2020 Feb 25, 2021	BUY	$51.77 - $66.18 $3.03 Million - $3.87 Million	58,527 New	58,527 $3.34 Million

Others Institutions Holding DCPH

# of Institutions

Shares Held

293K

Call Options Held

500

Put Options Held

View Full List

About Deciphera Pharmaceuticals, Inc.

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

More about DCPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.

Account